Suppr超能文献

Bleselumab 在预防肾移植受者原发性局灶节段性肾小球硬化复发中的疗效和安全性:一项 2a 期、随机、多中心研究。

Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study.

机构信息

Division of Transplant Nephrology, University of California San Francisco, San Francisco, CA.

Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.

出版信息

Transplantation. 2024 Aug 1;108(8):1782-1792. doi: 10.1097/TP.0000000000004985. Epub 2024 Jul 20.

Abstract

BACKGROUND

Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40-related processes in FSGS, potentially preventing rFSGS.

METHODS

A phase 2a, randomized, multicenter, open-label study of adult recipients (aged ≥18 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS. The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received basiliximab induction. The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant.

RESULTS

Sixty-three patients were followed for 12 mo posttransplantation. Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, -89.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, -34.5 to 9.0]). Central-blinded biopsy review found relative (absolute) decreases in rFSGS of 10.9% (3.9%), 17.0% (6.2%), and 20.5% (7.5%) at 3, 6, and 12 mo posttransplant, respectively; these differences were not statistically significant. Adverse events were similar for both treatments. No deaths occurred during the study.

CONCLUSIONS

In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed.

摘要

背景

局灶节段性肾小球硬化症(FSGS)是终末期肾病的常见病因,肾移植后常复发。复发性 FSGS(rFSGS)与移植物和患者预后不良相关。Bleselumab 是一种完全人源 IgG4 抗 CD40 拮抗单克隆抗体,可破坏 FSGS 中的 CD40 相关过程,从而可能预防 rFSGS。

方法

这是一项针对成人接受活体或已故供体肾移植的 2a 期、随机、多中心、开放标签研究,这些患者有活检证实的原发性 FSGS 病史。该研究评估了 bleselumab 联合他克莫司和皮质类固醇作为维持免疫抑制治疗在预防移植后 12 个月以上 rFSGS 方面的疗效,与包括他克莫司、霉酚酸酯和皮质类固醇的标准治疗(SOC)相比。所有患者均接受巴利昔单抗诱导。主要终点是 rFSGS,定义为蛋白尿(蛋白尿-肌酐比≥3.0 g/g)伴死亡、移植物丢失或失访,通过移植后 3 个月推断为 rFSGS。

结果

63 例患者在移植后 12 个月时进行了随访。与 SOC 相比,bleselumab 组在 3 个月时 rFSGS 发生率的相对下降为 40.7%(95%置信区间,-89.8 至 26.8;P=0.37;绝对下降 12.7%[95%置信区间,-34.5 至 9.0])。中心盲法活检评估发现,rFSGS 在移植后 3、6 和 12 个月时的相对(绝对)下降分别为 10.9%(3.9%)、17.0%(6.2%)和 20.5%(7.5%);这些差异无统计学意义。两种治疗的不良反应相似。研究期间无死亡发生。

结论

在高危肾移植受者中,bleselumab 与 SOC 相比可减少蛋白尿的发生,但在活检证实的 rFSGS 发生率方面未观察到显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f2d/11262731/fffb167ac9c6/tpa-108-1782-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验